Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMaximilian StahlPKPaul KollerMMMonzr M. Al Malki

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates improved event free survival in AML patients treated with azacitidine and venetoclax.

Key Points

  • To compare the efficacy and safety of azacitidine and venetoclax versus standard induction chemotherapy in fit adults with acute myeloid leukemia.
  • Open-label, multicenter, phase II randomized clinical trial
  • Compared azacitidine and venetoclax (aza-ven) to conventional induction chemotherapy
  • Secondary endpoints included overall survival, toxicity, and quality of life
  • Aza-ven significantly improved event free survival (EFS) compared to induction chemotherapy (HR 0.61; P=0.017)
  • Overall response rates were higher in aza-ven arm (88% vs. 62%; P<0.001)
  • Patients on aza-ven experienced significantly improved quality of life and had fewer hospital days compared to induction chemotherapy

Cite This Study

Stahl et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e189https://doi.org/10.1182/blood-2025-6
View Full Paper
Ask AI
Bookmark
Share